Search Results for "Odac Marqibo 2012"

17:55 EDT 30th September 2014 | BioPortfolio

Matching Channels

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Coronavirus

Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...

Veregen

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...

PATHSEEK

Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...

Matching News

Applying Avastin's lessons

ODAC rebuffed early approval of AZ's olaparib for ovarian cancer to avoid an Avastin-like scenario, where initial PFS didn't bear out.

Big biotech, Spectrum Pharma and CASI Pharma signed a licensing agreement

China-based, CASI has signed a licensing agreement with big biotech, Spectrum Pharma’s for its products: Zevalin, Marqibo and Melphalan. CASI has been granted exclusive rights to two of Spectrum...

FDA panel: AstraZeneca olaparib not ready to fly solo

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 11-2 the safety and efficacy results of AstraZeneca's single trial, known as study 19, in patients with germline BRCA mutation (gBRCAm) ovaria...

FDA panel: AstraZeneca's olaparib not ready to fly solo

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 11-2 the safety and efficacy results of AstraZeneca's single trial, known as study 19, in patients with germline BRCA mutation (gBRCAm) ovaria...

FDA questions validity/reproducibility of AstraZeneca's olaparib efficacy data

In briefing documents released ahead of a 25 June meeting of the agency's Oncologic Drugs Advisory Committee (ODAC), regulators also raised concerns about the risks associated with olaparib therapy, s...

FDA Committee Rejects Cancer Drug Accelerated Approval

AstraZeneca announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated...

Accelerated Approval Unlikely for AstraZeneca’s Ovarian Cancer Drug

The results of a recent vote by the FDA’s Oncologic Drugs Advisory Committee (ODAC) elicited audible groans from the audience in the agency’s Great Room. By a 9 to 2 tally, committee members had d...

Spectrum out-licenses rights for China to CASI Pharmaceuticals for three of its drugs

Spectrum Pharmaceuticals (SPPI) and CASI Pharmaceuticals have signed license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, ...

Matching PubMed Articles

Proceedings of the 2012 Sino-European Symposium on Environment and Health (SESEH 2012), August 20-25, 2012, Galgay, Ireland.

Introduction to the special issue for ISAF-ECAPD-PFM 2012.

This special issue contains some of the papers presented at the joint ISAF-ECAPD-PFM 2012 meeting, combining the 21st IEEE International Symposium on Applications of Ferroelectrics (ISAF 2012), the 11...

Treasurer's Report, 2012 Statement of Activities For the year ending December 31, 2012.

The analysis of infant mortality in Omsk oblast in 2002-2012.

In Omsk oblast during 2002-2012 a stable increase of birth rate is noted. Against the background of birth rate increase up to 2011 a positive dynamics of decrease of infant mortality was noted. In 201...

High-dose Vincristine Sulfate Liposome Injection (Marqibo) Is Not Associated With Clinically Meaningful Hematologic Toxicity.

Vincristine sulfate liposome injection (VSLI) facilitates vincristine dose intensification and densification, is active in untreated and relapsed lymphoma, and has been approved in the United States f...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement